Jaguar Health, Inc.
26.7.2021 14:31:52 CEST | ACCESS Newswire | Press release
Registration link for webcast appears below
SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte, the company's founder, president, and CEO, will be aired during an investor webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to provide business updates for Jaguar, Napo Pharmaceuticals, Inc. (Jaguar's wholly owned subsidiary), and the Italian subsidiary of Napo Pharmaceuticals, Napo EU S.p.A., which, with Dragon SPAC S.p.A., recently announced the closing of the financing of Dragon SPAC for gross proceeds of approximately 8,830,000 euros. The registration link for the webcast appears below.
Participation Instructions for Webcast
When: Thursday, July 29, 2021, at 8:30 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place July 29, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656646/Jaguar-Health-Announces-that-Innovators-with-Jane-King-Interview-with-Lisa-Conte-will-Air-During-Jaguar-Investor-Webcast-on-Thursday-July-29-2021-at-830-AM-Eastern-to-Provide-Business-Updates
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Global Anti-Scam Alliance Launches Scam.org with OpenAI and Key Partners12.3.2026 11:00:00 CET | Press release
AI technology meets on-the-ground expertise from leading organizations across five continents, accessible to billions of consumers in 50+ languages covering 97% of global internet users. AMSTERDAM, NL / ACCESS Newswire / March 12, 2026 / The Global Anti-Scam Alliance (GASA) launched today Scam.org, an AI-powered platform that provides scam education, prevention, detection, reporting, and victim support in over 50 languages, making it a new global hub, accessible to 97% of the world's internet users. Scam.org is powered by partnerships with OpenAI and leading cybersecurity organizations, AnyTech365, CUBE AI,Falkin, Malwarebytes, Netcraft, ReasonLabs, ScamAdviser, Scamnetic, Seraph Secure and Spamhaus. For personal victim support, Scam.org collaborates with other victim support organizations such as AARPin the USA and ANVINT in Brazil. The platform expects more organizations to join, with plans to build an even stronger and broader coalition, creating a world where people are safer from
LiberNovo: From Spring Cleaning to Physical Renewal12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / As the annual ritual of spring cleaning approaches, a new movement in functional design is shifting the focus from tidying desks to restoring the bodies that sit at them. LiberNovo, a pioneer in health-first design, has announced its spring initiative: a fundamental reimagining of the smart workspace that prioritizes physical fluidity over static organization. New Season, New Standards For decades, office chair ergonomics centered on the "90-degree rule"-a rigid posture that modern research suggests is counterproductive. The true culprit of office fatigue isn't just sitting; it is the lack of movement. Prolonged static positions compress the spine and reduce circulation. LiberNovo's philosophy asserts that a "Spring Reset" is incomplete if it only addresses surface-level clutter while leaving the body in a state of constant strain. Engineering Movement At the core of this movement is the LiberNovo Omni, a chair designed to master Dynam
LiberNovo Omni Wins iF DESIGN AWARD 2026 for Breakthrough Ergonomic Design12.3.2026 09:00:00 CET | Press release
HONG KONG, HK / ACCESS Newswire / March 12, 2026 / LiberNovo is proud to announce that its leading product, the LiberNovo Omni, has won the prestigious iF DESIGN AWARD 2026 in the Product Design - Beauty/Wellness category. The iF DESIGN AWARD is one of the most esteemed design competitions in the world, honoring outstanding design achievements in terms of innovation, functionality, and user experience. Developed to revolutionize the experience of sitting for long periods, the LiberNovo Omni is a product that creates a new category of seating solutions: the Dynamic Ergonomic Chair. The chair doesn't lock people into fixed positions; it accommodates natural body positions and movement throughout the day. This award-winning chair features intelligent ergonomic technologies to enhance user comfort, spinal health, and support movement. These include LiberNovo's innovative Dynamic Support, which automatically adjusts to changing postures, and an adjustable ergonomic framework designed to ens
Tenstorrent Unveils TT-QuietBox(TM) 2, the First RISC-V AI Workstation With a Fully Open-Source Stack to Deliver Teraflop-Class Inference11.3.2026 17:00:00 CET | Press release
Liquid-Cooled Desktop System Runs Models up to 120B Parameters Locally With a Fully Open-Source Stack, Starting at $9,999 SANTA CLARA, CA / ACCESS Newswire / March 11, 2026 / Tenstorrent, the AI computing company led by CEO Jim Keller, today announced TT-QuietBox™ 2 (Blackhole™). This whisper-quiet, liquid-cooled AI workstation runs models up to 120 billion parameters directly at your desk, ships with an entirely open-source software stack from compiler to kernel, and starts at $9,999. It marks the industry's first desktop AI workstation built on RISC-V architecture to deliver teraflop-class inference. The Inference Imperative The timing matters. Inference has quietly overtaken training as the dominant AI workload, now accounting for more than 55% of cloud AI infrastructure spending at $37.5 billion - and it is still accelerating. Yet, developers running these workloads face a stark choice: pay per-token cloud fees that compound as usage scales, or buy hardware locked to proprietary st
Clockwork.io Introduces A New Class of Fault Tolerance to End Failure-Driven GPU Waste in AI Training11.3.2026 14:00:00 CET | Press release
New TorchPass solution addresses a multi-million dollar challenge with AI infrastructure; uses Live GPU Migration to keep large-scale AI training running through hardware failures instead of forcing costly restarts PALO ALTO, CA / ACCESS Newswire / March 11, 2026 / Clockwork.io, the leader in Software-Driven AI Fabrics™- a programmable, vendor-neutral software layer that optimizes large-scale GPU clusters for real-time observability, fault tolerance, and deterministic performance-today announced the general availability of TorchPass Workload Fault Tolerance. This new class of software-driven fault-tolerance eliminates one of the most costly failure modes in large-scale AI training: catastrophic job restarts caused by infrastructure faults. Delivered as a core capability of the Clockwork.io FleetIQ™ platform, TorchPass applies the principles of Software-Driven AI Fabrics to distributed training, using Live GPU Migration to allow workloads to continue running through GPU failures, networ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom